Advertisement
David A. Eatwell, 47, joins Genmab with extensive experience and a proventrack record in leading international life science businesses, having spent15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwellserved as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD1.8 billion leading provider of manufacturing and packaging services for thepharmaceutical and biotech industry, with 33 facilities in 12 countries and10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO ofCardinal Health, Inc., a fortune 20 global manufacturer and distributor ofhealthcare products and services, where he spearheaded the USD 3.3 billionsale of the Pharmaceutical Technologies and Services division to TheBlackstone Group and was instrumental in creating the framework and buildingthe infrastructure to support the newly created company, Catalent PharmaSolutions, Inc. Mr. Eatwell is a Chartered Accountant.
Advertisement
Mr. Eatwell is replacing Bo Kruse who has decided to seek new challengeselsewhere, but will during a transitional period be available for the company.
"We are very excited to have David Eatwell on board to be part of ourSenior Management team and we are looking forward to working with him. Wealso wish to thank Bo Kruse for his many years of dedicated service toGenmab, and important contributions to the company. We wish Bo Kruse the bestof luck in his future endeavors and would like to thank him for his effortsat Genmab since 2000", said Lisa N. Drakeman, Ph.D., Chief Executive Officerof Genmab.
About Genmab A/S Genmab is a leading international biotechnology companyfocused on developing fully human antibody therapeutics for unmet medicalneeds. Using cutting-edge antibody technology, Genmab's world classdiscovery, development and manufacturing teams have created and developed anextensive pipeline of products for potential treatment of a variety ofdiseases including cancer and autoimmune disorders. As Genmab advancestowards a commercial future, we remain committed to our primary goal ofimproving the lives of patients who are in urgent need of new treatmentoptions. For more information on Genmab's products and technology, visithttp://www.genmab.com.
This press release contains forward looking statements. The words"believe", "expect", "anticipate", "intend" and "plan" and similarexpressions identify forward looking statements. Actual results orperformance may differ materially from any future results or performanceexpressed or implied by such statements. The important factors that couldcause our actual results or performance to differ materially include, amongothers, risks associated with product discovery and development,uncertainties related to the outcome and conduct of clinical trials includingunforeseen safety issues, uncertainties related to product manufacturing, thelack of market acceptance of our products, our inability to manage growth,the competitive environment in relation to our business area and markets, ourinability to attract and retain suitably qualified personnel, theunenforceability or lack of protection of our patents and proprietary rights,our relationships with affiliated entities, changes and developments intechnology which may render our products obsolete, and other factors. Genmabis not under an obligation to up-date statements regarding the futurefollowing the publication of this release; nor to confirm such statements inrelation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM);HuMax-CD3
